Short answer
MBX Biosciences, Inc. (MBX) filed an 8-K current report with the SEC on August 27, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). First patient dosed in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide.
MBX Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- First patient dosed in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide
- Target indication: adults with hypoparathyroidism
- Phase 3 initiation advances canvuparatide toward potential registration and commercial launch
- Exhibit 99.1 contains the company’s detailed trial and program information
Item 8.01 · Other Events
- First patient dosed in pivotal Phase 3 oPTimize trial, advancing canvuparatide toward potential registration
- Global randomized trial targeting approximately 160 chronic hypoparathyroidism patients, with 26-week placebo-controlled treatment
- 3:1 randomization favors canvuparatide, followed by a 78-week open-label extension for longer-term safety and durability
- Primary endpoint requires normal calcium, vitamin D independence, calcium supplementation ≤600 milligrams daily, and dose stability
- Commercial-intended device and once-weekly dosing could support differentiation if efficacy and safety succeed, but regulatory and funding risks remain significant
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MBX Biosciences, Inc. 8-K filings
Get the next MBX 8-K as it lands
Follow MBX for push alerts, or ask the research agent what this filing means.